Expert Discusses Ongoing Immunotherapy Research in CRC – Targeted Oncology
Targeted Oncology |
Expert Discusses Ongoing Immunotherapy Research in CRC
Targeted Oncology They are very responsive to immunotherapies. In fact, we have seen FDA approvals of pembrolizumab for patients with MSI-H cancers, as well as nivolumab for MSI-H CRC, which shows what the benefit of these agents can be for these patients with CRC. |
